GAIA BioMedicine, Inc., a technology-driven biopharmaceutical firm specialized in cell treatments and immunotherapies for intractable malignancies, was created in 2015 as a spin-off venture of Kyushu University. The firm name, GAIA, reflects the company's aim and vision as we fight intractable diseases with the strength of genes and the immune system as the rod of Asclepius, the Greek god of medicine.

Kangstem Biotech develops technology to isolate the non-hematological system stem cell with conversion and purity from the cord blood and to culture large quantity. Its Furestem therapies include Furestem-AD, Furestem-RA and Furestem-CD. Its businesses include cord blood-derived stem cell therapy business; cord blood-derived stem cell conditioned media business; and stem cell culture media business.

Part of Miltenyi GmbH, Miltenyi Biotec BV & Co. KG is a company headquartered in Bergisch Gladbach, Germany, that manufactures pharmaceutical products.

San Raffaele Hospital is one of the top centers of Gruppo San Donato (Italy’s largest hospital group, treating over 4.7 million patients yearly). San Raffaele University & Research Hospital is an institute that incorporates clinical, research and university activities altogether, while being internationally recognized for its specialization in some of the most complex pathologies. The hospital is a multi-specialty center with more than 50 clinical specialties covered and over 1300 beds, which is accredited by the Italian National Health System to provide treatment to both public and private, national and international patients. In 2016, the San Raffaele Hospital performed nearly 51,000 patient admissions, 67,700 emergency room interventions and delivered over 7 million healthcare services, including outpatient appointments and diagnostic exams. It is considered to be the most famous hospital in the country and among the most reputable medical centers in Europe.

Calpis Co., Ltd. produces lactic acid drinks and confectioneries. It also offers concentrated beverages, seasonal gift sets, ready-to-drink beverages, chilled, dairy products, and alcoholic beverages. The company was founded on April 1, 1982 and is headquartered in Tokyo, Japan.

PLTTECH engages in the R&D of single-cell precision research solutions. It is based on single-cell research in the field of precision medicine, and applies technological research and innovation to disease research and health management. The company aggregates the world's leading technologies such as single-cell detection, protein dynamic detection, and biological big data analysis, and provides excellent solutions for precision medicine and health management through extensive cooperation in the fields of medical scientific research, clinical diagnosis and treatment, and drug research and development. The company was founded in 2015 and is based in Hangzhou, China.

Shen Zhen Shi Sai Li Jian Sheng Wu Ke Ji You Xian Gong Si, established on 2012-06-29, Business scope includes general business items:Biotechnology Development and Technical Consulting;Provide logistics management services for medical institutions(Excluding self-run medical institutions);Invest in the medical industry(Specific projects will be approved separately);Domestic Trade(law,Administrative regulations,Except for projects that are required to be approved before registration by decision of the State Council).,The licensing program is:

Institut Jean Paoli & Irene Calmettes is a non-profit organization engaging in fighting cancer. The company is headquartered in Marseille, France.

La Jolla Institute for Allergy & Immunology is an American private company located in La Jolla, CA. The firm operates as a biomedical research institute helps in understanding of immune system disease. It was founded by Steve Pontell. Erica Saphire is currently the CEO of the company.\nThe company says this about itself: The La Jolla Institute for Immunology is dedicated to understanding the intricacies and power of the immune system so that we may apply that knowledge to promote human health and prevent a wide range of diseases. Since its founding in 1988 as an independent, nonprofit research organization, the Institute has made numerous advances leading toward its goal: life without disease.

Celgene Corporation is an American biotechnology company that discovers, develops and commercializes medicines for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company's major product is Revlimid (lenalidomide), in combination with dexamethasone for the treatment of multiple myeloma patients. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia, due to Low- or Intermediate-1-risk Myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Revlimid is sold through proprietary risk-management distribution programs, to ensure safe and appropriate use of these pharmaceuticals. Vidaza is approved for the treatment of patients with MDS.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Part of Founders Combined Charity Income Common Investment Fund, Fondazione Telethon is an Italian company located in Rome that operates as a healthcare charity.\nThe company says this about itself: Fondazione Telethon is a non-profit organisation created in 1990 as a response to the appeals of a patient association group of stakeholders, who saw scientific research as the only real opportunity to effectively fight genetic diseases. Thanks to the funds raised through the television marathon, along with other initiatives and a network of partners and volunteers, Telethon finances the best scientific research on rare genetic diseases, evaluated and selected by independent internationally renowned experts, with the ultimate objective of making the treatments developed available to everyone who needs them. Throughout its 30 years of activity, Fondazione Telethon has invested more than �� 528 million in funding more than 2.630 projects to study more than 570 diseases, involving over 1.600 scientists. Fondazione Telethon has made a significant contribution to the worldwide advancement of knowledge regarding rare genetic diseases and of academic research and drug development with a view to developing treatments.

Sinite Biotechnology Co., Ltd., established on 2019-08-16, Business scope includes pharmaceuticals,cosmetic,Health Supplies,Medical device research and development,technology transfer,technical consulting,Technical Services;Sales:cosmetic,Health Supplies;Import and export of goods and technology;Conference and Exhibition Services.Sales:medicine,medical instruments.(Did not obtain the relevant administrative license(approval),Do not carry out business activities).(The above business scope does not include items restricted or prohibited by national laws and regulations,Except those involving the implementation of special access management measures stipulated by the state,Business activities involving licenses can only be carried out with relevant licenses).

Eutilex Co., Ltd. develops anti-tumor T cell therapy and antibody therapeutics based on proprietary immunotherapy technology. It offers T Cell Therapy, Antibody, CAR-T Cell Therapy. The company was founded by Kwon Byoung S on February 27, 2015 and is headquartered in Seoul, South Korea.